Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming. Yu T, Liu Z, Tao Q, Xu X, et al. Cancer Lett 2024;589:216824.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Yu T, Liu Z, Tao Q, Xu X, et al. Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming. Cancer Lett 2024;589:216824.
PMID: 38522774